About CiceroDx, Inc.CiceroDx, Inc. is a diagnostics company dedicated to the advancement of clinical assays for understudied diseases.
Endometriosis is a major focus of CiceroDx, now offering for the first time a global test for all stages of endometriosis. This disease affects over 176 million women and takes 11 years on average to diagnose. Many women spend years dealing with pain, infertility and bowel or bladder symptoms without knowing that endometriosis is the cause.
CEO & President: Christopher Jackson
3 articles with CiceroDx, Inc.
These tests can also have meaningful impact on women struggling with unexplained infertility by giving them an answer to their infertility and providing treatment options to aid in getting pregnant.
New Clinical Study Further Validates Use of ReceptivaDx™ (BCL6) Testing for Women with Unexplained Infertility by Demonstrating Successful Treatment Outcomes, Improved Live Birth Rates and Reduced Miscarriage Rates
CiceroDx, Inc., a women’s healthcare diagnostic company, is pleased to announce the publication of a pivotal study demonstrating the effectiveness of both medical or surgical treatment in unexplained infertility patients with abnormal endometrial BCL6 expression.